AP3346A - Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same - Google Patents

Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same

Info

Publication number
AP3346A
AP3346A AP2012006191A AP2012006191A AP3346A AP 3346 A AP3346 A AP 3346A AP 2012006191 A AP2012006191 A AP 2012006191A AP 2012006191 A AP2012006191 A AP 2012006191A AP 3346 A AP3346 A AP 3346A
Authority
AP
ARIPO
Prior art keywords
same
preparing
pharmaceutical composition
composition containing
novel compounds
Prior art date
Application number
AP2012006191A
Other languages
English (en)
Other versions
AP2012006191A0 (en
Inventor
Tae Hun Kim
Eun Sil Choi
Heui Sul Park
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43857261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AP2012006191A0 publication Critical patent/AP2012006191A0/xx
Application granted granted Critical
Publication of AP3346A publication Critical patent/AP3346A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2012006191A 2009-10-07 2010-10-04 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same AP3346A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090095363 2009-10-07
PCT/KR2010/006760 WO2011043568A2 (en) 2009-10-07 2010-10-04 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same

Publications (2)

Publication Number Publication Date
AP2012006191A0 AP2012006191A0 (en) 2012-04-30
AP3346A true AP3346A (en) 2015-07-31

Family

ID=43857261

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006191A AP3346A (en) 2009-10-07 2010-10-04 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same

Country Status (26)

Country Link
US (1) US8729273B2 (de)
EP (1) EP2467378B1 (de)
JP (1) JP5702392B2 (de)
KR (1) KR101751325B1 (de)
CN (1) CN102574839B (de)
AP (1) AP3346A (de)
AR (1) AR078504A1 (de)
AU (1) AU2010304091B2 (de)
BR (1) BR112012007828B8 (de)
CA (1) CA2774133C (de)
CL (1) CL2012000738A1 (de)
CO (1) CO6430501A2 (de)
EA (1) EA021025B1 (de)
EC (1) ECSP12011793A (de)
ES (1) ES2599829T3 (de)
IL (1) IL218669A (de)
MA (1) MA33880B1 (de)
MX (1) MX2012003782A (de)
MY (1) MY162813A (de)
PE (1) PE20121088A1 (de)
SG (1) SG179186A1 (de)
TR (1) TR201203989T1 (de)
TW (1) TWI423962B (de)
UA (1) UA110197C2 (de)
WO (1) WO2011043568A2 (de)
ZA (1) ZA201202544B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
PE20142081A1 (es) * 2011-08-30 2014-12-18 Chdi Foundation Inc Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
NZ712680A (en) 2013-03-29 2020-02-28 Teijin Pharma Ltd Pyrazole derivative
CN114588157A (zh) 2014-07-17 2022-06-07 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
CN104774172B (zh) * 2015-04-08 2017-03-22 河南师范大学 一种3‑氰基吲哚类化合物的合成方法
EP3344604B1 (de) * 2015-09-02 2020-11-04 Sunshine Lake Pharma Co., Ltd. Carboxy-substituierte (hetero) aromatische ringderivate und herstellungsverfahren und verwendungen davon
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
KR20260008164A (ko) 2016-12-02 2026-01-15 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
WO2018157801A1 (zh) * 2017-02-28 2018-09-07 广东东阳光药业有限公司 氰基取代的稠合双环衍生物及其制备方法和用途
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
JP7177577B2 (ja) 2018-06-01 2022-11-24 オートファジーサイエンシーズ インコーポレイテッド 新規な化合物およびこれを含む薬学的組成物
CN111072647B (zh) * 2019-12-11 2021-02-26 沈阳药科大学 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
WO2022098057A1 (ko) * 2020-11-04 2022-05-12 주식회사 엘지화학 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정성 입자의 제조방법 및 이를 포함하는 약학적 조성물
CN116528852A (zh) * 2020-12-01 2023-08-01 株式会社Lg 化学 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的稳定的口服制剂
EP4257124A4 (de) * 2020-12-01 2024-05-29 Lg Chem, Ltd. Orale formulierung mit 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carbonsäure und verfahren zur herstellung davon
CN112920170B (zh) * 2021-01-29 2023-06-20 中国医科大学 N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途
US20240216331A1 (en) * 2021-04-16 2024-07-04 Lg Chem, Ltd. Oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
CN117255785A (zh) * 2021-04-27 2023-12-19 株式会社Lg化学 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法
CN117203200A (zh) * 2021-04-27 2023-12-08 株式会社Lg化学 黄嘌呤氧化酶抑制剂的制备方法
CN117242062A (zh) * 2021-04-27 2023-12-15 株式会社Lg化学 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法
EP4335844A4 (de) 2021-05-07 2025-08-27 Jiangsu Atom Bioscience And Pharmaceutical Co Ltd Klasse von xanthinoxidasehemmern
PE20240242A1 (es) * 2021-06-15 2024-02-16 Lg Chemical Ltd Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
TWI822151B (zh) * 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
BR112023026062A2 (pt) * 2021-07-02 2024-03-05 Lg Chemical Ltd Método para preparar um composto
CN116836154B (zh) * 2022-04-27 2026-01-23 杭州新元素药业股份有限公司 可用于痛风的化合物
WO2023208108A1 (zh) * 2022-04-27 2023-11-02 江苏新元素医药科技有限公司 可用于降尿酸的化合物
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用
KR20250009377A (ko) 2023-07-10 2025-01-17 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
CN118598859B (zh) * 2024-05-21 2025-08-19 武汉工程大学 一种含氮杂环吲哚类黄嘌呤氧化酶抑制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
WO2008126898A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. （アザ）インドール誘導体及びその医薬用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE142494T1 (de) 1990-11-30 1996-09-15 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
CA2414468A1 (en) * 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU6872701A (en) * 2000-07-10 2002-01-21 Bristol Myers Squibb Co Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
US20090149452A1 (en) * 2005-07-01 2009-06-11 Nippon Chemiphar Co., Ltd. Xanthine oxidase inhibitor
WO2007043457A1 (ja) 2005-10-07 2007-04-19 Astellas Pharma Inc. トリアリールカルボン酸誘導体
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2008179621A (ja) * 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
WO2008126770A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
CN101679244B (zh) 2007-04-11 2014-01-01 橘生药品工业株式会社 5元杂环衍生物及其医药用途
EP2338887A4 (de) 2008-10-15 2012-05-09 Kissei Pharmaceutical Kondensiertes heterozyklisches derivat und seine verwendung für medizinische zwecke
AU2009303519B2 (en) 2008-10-16 2014-09-25 Automatic Bar Controls, Inc. Apparatus and method and turntable for on-demand distributing of a food product
WO2010045188A1 (en) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
JP2013505913A (ja) * 2009-09-24 2013-02-21 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒａｃ調節剤としてのインドール誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
WO2008126898A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. （アザ）インドール誘導体及びその医薬用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KELVIN BILLINGSLEY ET AL: "Highly Efficient Monophosphine-Based Catalyst for the Palladium-Catalyzed Suzuki-Miyaura Reaction of Heteroaryl Halides and Heteroaryl Boronic Acids and Esters", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 11, 1 March 2007 (2007-03-01), pages 3358 - 3366, XP055056735 *

Also Published As

Publication number Publication date
AU2010304091B2 (en) 2016-06-09
KR20110037883A (ko) 2011-04-13
CN102574839A (zh) 2012-07-11
EP2467378A2 (de) 2012-06-27
MX2012003782A (es) 2012-08-31
IL218669A (en) 2016-08-31
UA110197C2 (ru) 2015-12-10
PE20121088A1 (es) 2012-08-17
BR112012007828A2 (pt) 2016-03-08
EP2467378A4 (de) 2013-04-24
CL2012000738A1 (es) 2012-09-14
WO2011043568A3 (en) 2011-09-29
MA33880B1 (fr) 2013-01-02
CO6430501A2 (es) 2012-04-30
ZA201202544B (en) 2012-12-29
BR112012007828B1 (pt) 2021-01-12
ECSP12011793A (es) 2012-05-30
HK1170224A1 (zh) 2013-02-22
KR101751325B1 (ko) 2017-06-27
EA201270520A1 (ru) 2012-10-30
AP2012006191A0 (en) 2012-04-30
WO2011043568A2 (en) 2011-04-14
IL218669A0 (en) 2012-05-31
BR112012007828B8 (pt) 2021-05-25
MY162813A (en) 2017-07-31
CA2774133C (en) 2019-06-25
ES2599829T3 (es) 2017-02-03
SG179186A1 (en) 2012-05-30
EA021025B1 (ru) 2015-03-31
JP5702392B2 (ja) 2015-04-15
US20120184582A1 (en) 2012-07-19
CN102574839B (zh) 2015-11-25
JP2013507355A (ja) 2013-03-04
TW201118077A (en) 2011-06-01
AR078504A1 (es) 2011-11-09
EP2467378B1 (de) 2016-07-27
US8729273B2 (en) 2014-05-20
TWI423962B (zh) 2014-01-21
AU2010304091A1 (en) 2012-04-19
TR201203989T1 (tr) 2012-09-21
CA2774133A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
AP3346A (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
HUS1700051I1 (hu) Pirrolopiridin vegyületek, mint CDK inhibitorok
ZA201608799B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
ZA201208198B (en) Picolinamide and pyrimidine-4-carboxamine compounds, process for preparing and pharmaceutical composition comprising the same
WO2010093191A3 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
IL223423A (en) History of 6.5 Dihydro-2 h- [1,4] Oxazin-3-Ill-Amine Used as Inhibitors in Scarlet Cell
IL207099A0 (en) 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace)
ZA201203183B (en) Sulfomethylsuccinates, process for making same and compositions containing same
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
MY144726A (en) Diosmetin compounds, process for their preparation and pharmaceutical compositions containing them
ZA201108292B (en) New compounds,pharmaceutical composition and methods relating thereto
EP2439198A4 (de) Neuartiges verfahren zur herstellung von rosuvastatin, zwischenverbindungen zu seiner herstellung und verfahren zu deren herstellung
ZA201103444B (en) Heteroaromatic compounds for use as hif inhibitors
IL207183A (en) Dihydroindolone compounds, a process for their preparation and their pharmaceutical compositions
PL2504331T3 (pl) Związek, jego nowe formy, zawierające je kompozycje farmaceutyczne i sposoby otrzymywania oraz zastosowanie
GB0800570D0 (en) Composition, process for preparation and method of use
IL203064B (en) A pharmaceutical preparation containing compound 11 - deoxy - prostaglandin and a method for stabilizing the compound
AP2011005885A0 (en) Flavanoid compounds and process for preparation thereof.
IL212850A0 (en) Novel method for the preparation of granulates of active constituents, and granulates as obtained
AP2012006352A0 (en) AzabicycloÄ3.1.0Ühex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same.
IL210049A0 (en) Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it
SI2332910T1 (sl) Novi derivati azabiciklo(3.2.0)hept-3-ila, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
HK1171733A (en) Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid
EP2289989A4 (de) Zusatz, verfahren zu seiner herstellung und zusammensetzung damit
HK1162499A (en) Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1